Background Antigen specific release of IP-10 is an established marker for infection with M.tuberculosis. Compared to IFN-γ, IP-10 is released in 100-fold higher concentrations enabling the development of novel assays for detection. Dried blood spots are a convenient sample for high throughput newborn screening. Aim To develop a robust and sensitive ELISA-based assay for IP-10 detection in plasma, dried blood spots (DBS) and dried plasma spots (DPS); to validate the ELISA in clinically relevant samples; and to assess the performance of the assay for detection of Cytomegalovirus (CMV) and M.tuberculosis specific immune responses. Method We raised mice and rat monoclonal antibodies against human IP-10 and developed an ELISA. The assay was validated and applied to the detection of CMV and M.tuberculosis specific responses in 18 patients with immune reactivity towards M.tuberculosis and 32 healthy controls of which 22 had immune reactivity towards CMV and none towards M.tuberculosis. We compared the performance of this new assay to IFN-γ. Results The ELISA was reliable for IP-10 detection in both plasma and filter paper samples. The linear range of the ELISA was 2.5–600 pg/ml. IFN-γ was not readily detectable in DPS samples. IP-10 was stabile in filter paper samples for at least 4 weeks at 37°C. The correlation between IP-10 detected in plasma, DPS and DBS samples was excellent (r2>0.97). Conclusions This newly developed assay is reliable for IP-10 quantification in plasma, DBS and DPS samples from antigen stimulated and non-stimulated whole blood. The filter paper assays enable easy sample acquisition and transport at ambient temperature e.g. via the postal system. The system can potentially simplify diagnostic assays for M.tuberculosis and CMV infection.
References
[1]
Groom JR, Luster AD (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol. Accessed 2011 Jan 12.
[2]
Ruhwald M, Aabye MG, Ravn P (2012) IP-10 release assays in the diagnosis of tuberculosis infection: current status and future directions. Expert Rev. Mol. Diagn. 12: 175–187. doi: 10.1586/erm.11.97.
[3]
Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. (2011) CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 22: 121–130. doi: 10.1016/j.cytogfr.2011.06.001.
[4]
Eloranta M-L, Franck-Larsson K, L？vgren T, Kalamajski S, R？nnblom A, et al. (2010) Type I interferon system activation and association with disease manifestations in systemic sclerosis. Ann. Rheum. Dis. 69: 1396–1402. doi: 10.1136/ard.2009.121400.
[5]
Kasprowicz VO, Halliday JS, Mitchell J, Klenerman P (2012) MIGRAs: are they the new IGRAs? Development of monokine-amplified IFN-γ release assays. Biomark Med 6: 177–186. doi: 10.2217/bmm.12.13.
[6]
Zeremski M, Dimova R, Astemborski J, Thomas DL, Talal AH (2011) CXCL9 and CXCL10 Chemokines as Predictors of Liver Fibrosis in a Cohort of Primarily African-American Injection Drug Users With Chronic Hepatitis C. Journal of Infectious Diseases 204: 832–836. doi: 10.1093/infdis/jir424.
[7]
Zeremski M, Petrovic LM, Talal AH (2007) The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection. J. Viral Hepat 14: 675–687. doi: 10. 1111/j.1365–2893.2006.00838.x.
[8]
Cannas A, Calvo L, Chiacchio T, Cuzzi G, Vanini V, et al. (2010) IP-10 detection in urine is associated with lung diseases. BMC infectious diseases 10: 333.
[9]
Kabeer BSA, Raja A, Raman B, Thangaraj S, Leportier M, et al. (2011) IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy. BMC Infect. Dis 11: 135. doi: 10.1186/14712334–11–135.
[10]
Azzurri A, Sow OY, Amedei A, Bah B, Diallo S, et al. (2005) IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes.Infect. 7: 1–8.
[11]
de Steenwinkel JEM, de Knegt GJ, Ten Kate MT, Verbrugh HA, Ottenhoff THM, et al. (2011) Dynamics of interferon-gamma release assay and cytokine profiles in blood and respiratory tract specimens from mice with tuberculosis and the effect of therapy. Eur. J. Clin. Microbiol. Infect. Dis. Accessed 2012 Jan 18.
[12]
Nie CQ, Bernard NJ, Norman MU, Amante FH, Lundie RJ, et al. (2009) IP-10-mediated T cell homing promotes cerebral inflammation over splenic immunity to malaria infection. PLoS Pathog. 5: e1000369. doi: 10.1371/journal.ppat.1000369.
[13]
Farber JM (1997) Mig and IP-10: CXC chemokines that target lymphocytes. J.Leukoc.Biol. 61: 246–257.
[14]
Narumi S, Finke JH, Hamilton TA (1990) Interferon gamma and interleukin 2 synergize to induce selective monokine expression in murine peritoneal macrophages. J. Biol. Chem. 265: 7036–7041.
[15]
Sauty A, Dziejman M, Taha RA, Iarossi AS, Neote K, et al. (1999) The T cell-specific CXC chemokines IP-10, Mig, and I-TAC are expressed by activated human bronchial epithelial cells. J. Immunol. 162: 3549–3558.
[16]
Karonitsch T, Dalwigk K, Steiner CW, Blüml S, Steiner G, et al. (2011) Interferon (IFN) signals and monocytic sensitization of the IFNγ signaling pathway in peripheral blood of rheumatoid arthritis patients. Arthritis and Rheumatism. Accessed 2011 Oct 3.
[17]
Ohmori Y, Wyner L, Narumi S, Armstrong D, Stoler M, et al. (1993) Tumor necrosis factor-alpha induces cell type and tissue-specific expression of chemoattractant cytokines in vivo. Am. J. Pathol. 142: 861–870.
[18]
Guzzo C, Che Mat NF, Gee K (2010) Interleukin-27 induces a STAT1/3- and NF-kappaB-dependent proinflammatory cytokine profile in human monocytes. J. Biol. Chem. 285: 24404–24411. doi: 10.1074/jbc.M110.112599.
[19]
Rudner XL, Happel KI, Young EA, Shellito JE (2007) Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 75: 3055–3061. doi: 10.1128/IAI.01329-06.
[20]
Khader SA, Bell GK, Pearl JE, Fountain JJ, Rangel-Moreno J, et al. (2007) IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8: 369–377. doi: 10.1038/ni1449.
[21]
Qian C, An H, Yu Y, Liu S, Cao X (2007) TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 109: 3308–3315. doi: 10.1182/blood-2006-08-040337.
[22]
Qi X-F, Kim D-H, Yoon Y-S, Jin D, Huang X-Z, et al. (2009) Essential involvement of cross-talk between IFN-gamma and TNF-alpha in CXCL10 production in human THP-1 monocytes. J. Cell. Physiol. 220: 690–697. doi: 10.1002/jcp.21815.
[23]
Kabeer BS, Sikhamani R, Raja A (2010) Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV-tuberculosis patients. [Letter]. AIDS 24: 323–325.
[24]
Aabye MG, Ruhwald M, Praygod G, Jeremiah K, Faurholt-Jepsen M, et al. (2010) Potential of interferon-{gamma}-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur. Respir. J 36: 1488–1490. doi: 10.1183/09031936.00039010.
[25]
Lighter J, Rigaud M, Huie M, Peng CH, Pollack H (2009) Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int.J Tuberc.Lung Dis. 13: 731–736.
[26]
Alsleben N, Ruhwald M, Rüssmann H, Marx FM, Wahn U, et al. (2011) Interferon-gamma inducible protein 10 as a biomarker for active tuberculosis and latent tuberculosis infection in children: A case–control study. Scandinavian Journal of Infectious Diseases: 1–7. doi: 10.3109/00365548.2011.632644.
[27]
Chen D-Y, Shen G-H, Chen Y-M, Chen H-H, Lin C-C, et al. (2011) Interferon-inducible protein-10 as a marker to detect latent and active tuberculosis in rheumatoid arthritis. Int. J. Tuberc. Lung Dis 15: 192–200.
[28]
Vanini V, Petruccioli E, Gioia C, Cuzzi G, Orchi N, et al. (2012) IP-10 is an additional marker for tuberculosis (TB) detection in HIV-infected persons in a low-TB endemic country. Journal of Infection. Accessed 2012 Apr 26.
[29]
Mei JV, Alexander JR, Adam BW, Hannon WH (2001) Use of filter paper for the collection and analysis of human whole blood specimens. J. Nutr 131: 1631 S–6 S.
[30]
McDade TW, Williams S, Snodgrass JJ (2007) What a drop can do: dried blood spots as a minimally invasive method for integrating biomarkers into population-based research. Demography 44: 899–925.
[31]
Snijdewind IJM, van Kampen JJA, Fraaij PLA, van der Ende ME, Osterhaus ADME, et al. (2012) Current and future applications of dried blood spots in viral disease management. Antiviral Research. Accessed 2012 Jan 19.
[32]
Levy HL (2010) Newborn screening conditions: What we know, what we do not know, and how we will know it. Genet. Med. 12: S213–214. doi: 10.1097/GIM.0b013e3181fe5d77.
[33]
Levy PA (2010) An overview of newborn screening. J Dev Behav Pediatr 31: 622–631. doi: 10.1097/DBP.0b013e3181eedf01.
[34]
Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF (2009) Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir. Ther. (Lond.) 14: 619–629.
[35]
Maritz J, Preiser W, van Zyl GU (2012) Establishing diagnostic cut-off criteria for the COBAS AmpliPrep/COBAS TaqMan HIV-1 Qualitative test through validation against the Amplicor DNA test v1.5 for infant diagnosis using dried blood spots. J. Clin. Virol. 53: 106–109. doi: 10.1016/j.jcv.2011.12.002.
[36]
Corran PH, Cook J, Lynch C, Leendertse H, Manjurano A, et al. (2008) Dried blood spots as a source of anti-malarial antibodies for epidemiological studies. Malar. J 7: 195. doi: 10.1186/1475-2875-7-195.
[37]
Skogstrand K, Thorsen P, N？rgaard-Pedersen B, Schendel DE, S？rensen LC, et al. (2005) Simultaneous measurement of 25 inflammatory markers and neurotrophins in neonatal dried blood spots by immunoassay with xMAP technology. Clin. Chem 51: 1854–1866. doi: 10.1373/clinchem.2005.052241.
[38]
Eising S, Svensson J, Skogstrand K, Nilsson A, Lynch K, et al. (2007) Type 1 diabetes risk analysis on dried blood spot samples from population-based newborns: design and feasibility of an unselected case-control study. Paediatr Perinat Epidemiol 21: 507–517. doi: 10.1111/j.1365–3016.2007.00846.x.
[39]
Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, et al. (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res 23: 312–328. doi: 10.1007/s11095-005-9045-3.
[40]
Aabye MG, Ravn P, Johansen IS, Eugen-Olsen J, Ruhwald M (2011) Incubation of whole blood at 39{degrees}C augments IP-10 and IFN-{gamma} responses to M. tuberculosis antigens. Clin Vaccine Immunol. Accessed 2011 Jun 5.
[41]
Krouwer JS, Rabinowitz R (1984) How to Improve Estimates of Imprecision. Clinical Chemistry 30: 290–292.
[42]
Kasprowicz VO, Mitchell JE, Chetty S, Govender P, Huang K-HG, et al. (2011) A molecular assay for sensitive detection of pathogen-specific T-cells. PLoS ONE 6: e20606. doi: 10.1371/journal.pone.0020606.
[43]
Walker S, Fazou C, Crough T, Holdsworth R, Kiely P, et al. (2007) Ex vivo monitoring of human cytomegalovirus specific CD8+ T-cell responses using QuantiFERON？-CMV. Transplant Infectious Disease 9: 165–170. doi: 10.1111/j.1399–3062.2006.00199.x.
[44]
Skogstrand K (2011) Multiplex assays of inflammatory markers, a description of methods and discussion of precautions - Our experience through the last ten years. Methods. Accessed 2012 Feb 1.
[45]
Skogstrand K, Ekelund CK, Thorsen P, Vogel I, Jacobsson B, et al. (2008) Effects of blood sample handling procedures on measurable inflammatory markers in plasma, serum and dried blood spot samples. J. Immunol. Methods 336: 78–84. doi: 10.1016/j.jim.2008.04.006.
[46]
Skogstrand K, Thysen AH, J？rgensen CS, Rasmussen EM, Andersen ？B, et al. (2012) Antigen-induced cytokine and chemokine release test for tuberculosis infection using adsorption of stimulated whole blood on filter paper and multiplex analysis. Scandinavian Journal of Clinical & Laboratory Investigation: 1–8. doi: 10.3109/00365513.2011.649014.
[47]
Hasan Z, Rao N, Salahuddin N, Islam M, Ashraf M, et al. (2011) M. tuberculosis sonicate induced IFNγCXCL10 and IL10 can differentiate severity in tuberculosis. Scandinavian Journal of Immunology. 75: 2. doi: 10.1111/j.1365-3083.2011.02642.x.
[48]
Ruhwald M, Bjerregaard-Andersen M, Rabna P, Kofoed K, Eugen-Olsen J, et al. (2007) IP-10/CXCL10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes.Infect. 9: 806–812.
[49]
Ruhwald M, Bjerregaard-Andersen M, Rabna P, Eugen-Olsen J, Ravn P (2009) IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with _M.Tuberculosis_ in a whole blood based T-cell assay. BMC.Res.Notes 2: 19.
[50]
Chegou N, Black G, Kidd M, van Helden P, Walzl G (2009) Host markers in Quantiferon supernatants differentiate active TB from latent TB infection: preliminary report. BMC Pulmonary Medicine 9: 21. doi: 10.1186/1471-2466-9-21.
[51]
Frahm M, Goswami ND, Owzar K, Hecker E, Mosher A, et al. (2011) Discriminating between latent and active tuberculosis with multiple biomarker responses. Tuberculosis (Edinb). Accessed 2011 Mar 25.
[52]
Kellar KL, Gehrke J, Weis SE, Mahmutovic-Mayhew A, Davila B, et al. (2011) Multiple Cytokines Are Released When Blood from Patients with Tuberculosis Is Stimulated with Mycobacterium tuberculosis Antigens. PLoS ONE 6: e26545. doi: 10.1371/journal.pone.0026545.
[53]
Sutherland JS, de Jong BC, Jeffries DJ, Adetifa IM, Ota MOC (2010) Production of TNF-alpha, IL-12(p40) and IL-17 can discriminate between active TB disease and latent infection in a West African cohort. PLoS ONE 5: e12365. doi: 10.1371/journal.pone.0012365.
[54]
Chen Y-C, Chin C-H, Liu S-F, Wu C-C, Tsen C-C, et al. (2011) Prognostic values of serum IP-10 and IL-17 in patients with pulmonary tuberculosis. Dis. Markers 31: 101–110. doi: 10.3233/DMA-2011-0808.
[55]
Riou C, Perez Peixoto B, Roberts L, Ronacher K, Walzl G, et al. (2012) Effect of Standard Tuberculosis Treatment on Plasma Cytokine Levels in Patients with Active Pulmonary Tuberculosis. PLoS ONE 7: e36886. doi: 10.1371/journal.pone.0036886.
[56]
Zeremski M, Hooker G, Shu MA, Winkelstein E, Brown Q, et al. (2011) Induction of CXCR3- and CCR5-associated chemokines during acute hepatitis C virus infection. J Hepatol. Accessed 2011 Aug 5.
[57]
Mei JV, Zobel SD, Hall EM, De Jesús VR, Adam BW, et al. (2010) Performance properties of filter paper devices for whole blood collection. Bioanalysis 2: 1397–1403. doi: 10.4155/bio.10.73.
[58]
Monleau M, Butel C, Delaporte E, Boillot F, Peeters M (2010) Effect of storage conditions of dried plasma and blood spots on HIV-1 RNA quantification and PCR amplification for drug resistance genotyping. Journal of Antimicrobial Chemotherapy 65: 1562–1566. doi: 10.1093/jac/dkq205.
[59]
Vu DH, Alffenaar JWC, Edelbroek PM, Brouwers JRBJ, Uges DRA (2011) Dried blood spots: a new tool for tuberculosis treatment optimization. Curr. Pharm. Des. 17: 2931–2939.
